Patents by Inventor Hervé Siendt
Hervé Siendt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11839613Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: December 12, 2023Assignee: Idorsia Pharmaceuticals LtdInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11712438Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: August 1, 2023Assignee: Idorsia Pharmaceuticals LtdInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11446298Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: September 20, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11325899Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: May 10, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Publication number: 20210113559Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 22, 2021Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20210115031Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 22, 2021Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20200179383Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: June 11, 2020Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20200108068Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 9, 2020Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Patent number: 10202368Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.Type: GrantFiled: November 30, 2015Date of Patent: February 12, 2019Assignee: IDORSIA PHARMACEUTICALS LTD.Inventors: Philippe Guerry, Francois Lehembre, Julien Pothier, Hervé Siendt
-
Publication number: 20180155344Abstract: The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.Type: ApplicationFiled: May 3, 2016Publication date: June 7, 2018Applicant: ACTELION PHARMACEUTICALS LTDInventors: Daniel BUR, Corinna GRISOSTOMI, Thierry KIMMERLIN, Lubos REMEN, Hervé SIENDT, Magali VERCAUTEREN, Richard WELFORD
-
Patent number: 9920010Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.Type: GrantFiled: May 28, 2014Date of Patent: March 20, 2018Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Heinz Fretz, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Julien Pothier, Hervé Siendt, Anja Valdenaire
-
Publication number: 20170327493Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.Type: ApplicationFiled: November 30, 2015Publication date: November 16, 2017Inventors: Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Hervé SIENDT
-
Publication number: 20160107997Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.Type: ApplicationFiled: May 28, 2014Publication date: April 21, 2016Inventors: Heinz FRETZ, Philippe GUERRY, Thierry KIMMERLIN, Francois LEHEMBRE, Julien POTHIER, Hervé SIENDT, Anja VALDENAIRE
-
Patent number: 8236818Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.Type: GrantFiled: March 28, 2008Date of Patent: August 7, 2012Assignee: Santhera Pharmaceuticals (Schweiz) AGInventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
-
Publication number: 20100324036Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression.Type: ApplicationFiled: December 18, 2008Publication date: December 23, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Michael Soeberdt, Philipp Weyermann, Herve Siendt, Sonja Nordhoff, Achim Feurer, Miroslav Terinek
-
Publication number: 20100249093Abstract: The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.Type: ApplicationFiled: July 18, 2008Publication date: September 30, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Marco Henneböhle, Holger Herzner, Michael Soeberdt, Philipp Weyermann, Sonja Nordhoff, Achim Feurer, Holger Deppe, Hervé Siendt, Miroslav Terinek, Christian Rummey
-
Publication number: 20100093697Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.Type: ApplicationFiled: March 28, 2008Publication date: April 15, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
-
Publication number: 20080058324Abstract: The present invention relates to novel a-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all condition where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: August 22, 2005Publication date: March 6, 2008Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Philipp Weyermann, Andreas Von Sprecher, Marco Hennebohle, Holger Herzner, Cyrille Lescop, Herve Siendt
-
Publication number: 20070293486Abstract: The present invention relates to novel ?-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all condition where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: August 22, 2005Publication date: December 20, 2007Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Philipp Weyermann, Andreas Von Sprecher, Marco Hennebohle, Holger Herzner, Cyrille Lescop, Herve Siendt
-
Publication number: 20060258598Abstract: The present invention relates to novel ?-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all conditions where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease (MCP) also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: March 3, 2004Publication date: November 16, 2006Inventors: Holger Herzner, Philipp Weyermann, Andreas Sprecher, Marco Henneböhle, Cyrille Lescop, Hervé Siendt